BLA 125427 · Genentech
Kadcyla
Ado-Trastuzumab Emtansine · Single-Use
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Feb 22, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
142
35 Phase 3, 21 recruiting
FAERS reports
8,459
6,979 serious, 1,171 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY Hepatotoxicity: Serious hepatotoxicity has been reported, including liver failure and death in patients treated with KADCYLA. Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Reduce dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases or total bilirubin. ( 2.3 , 5.1 ) Cardiac Toxicity: KADCYLA administration may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and during treatment with KADCYLA. Withhold treatment for clinically significant decrease in left ventricular function. ( 2.3 , 5.2 ) Embryo-Fetal Toxicity: Exposure to KADCYLA during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective...
What it is approved for
From the label in effect Apr 1, 2026.
KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-authorized test for KADCYLA [see Dosage and Administration (2.1) ] 1.1 Metastatic Breast Cancer (MBC) KADCYLA ® , as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or Developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-authorized test for KADCYLA [ see Dosage and Administration (2.1) ]. 1.2 Early Breast Cancer (EBC) KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment. Select patients for therapy based on an FDA-authorized test for KADCYLA [ see Dosage and Administration (2.1) ].
Mechanism: Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate. The antibody is the humanized anti-HER2 IgG1, trastuzumab. The small molecule cytotoxin, DM1, is a microtubule inhibitor. Upon binding to sub-domain IV of the HER2 receptor, ado-trastuzumab emtansine undergoes receptor-mediated internalization and subsequent lysosomal degradation, resulting in intracellular release of DM1-containing cytotoxic catabolites. Binding of DM1 to tubulin disrupts microtubule networks in the cell, which results in cell cycle arrest and apoptotic cell death. In addition, in vitro studies have shown...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 14, 2025 Supplement 121 · Efficacy LabelLetter
- May 3, 2019 Supplement 105 · Efficacy · priority review LabelLetter
- Feb 22, 2013 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewOther Important Information from FDA
2 products under this application
- KADCYLA · ADO-TRASTUZUMAB EMTANSINE 100MG · VIAL, SINGLE-USE · Prescription
- KADCYLA · ADO-TRASTUZUMAB EMTANSINE 160MG · VIAL, SINGLE-USE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ado-Trastuzumab Emtansine" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01702571 · 2,185 participants · Start Nov 27, 2012 · Primary completion Jul 31, 2020
Drug: Trastuzumab Emtansine · For: Breast Cancer
Sites: Buenos Aires, Argentina; La Rioja, Argentina; Mar del Plata, Argentina · 300 sites in all
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04266249 · 2,175 participants · Start Mar 13, 2020 · Primary completion Oct 31, 2027
Drug: Docetaxel; Nab-paclitaxel and 4 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8 and 6 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,008 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01966471 · 1,846 participants · Start Jan 31, 2014 · Primary completion Nov 27, 2019
Drug: Trastuzumab Emtansine; Trastuzumab and 7 more · For: Breast Cancer
Sites: Scottsdale, Arizona; Oakland, California; Roseville, California · 295 sites in all
- A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06126640 · 1,615 participants · Start Nov 20, 2023 · Primary completion Apr 2030
Drug: SHR-A1811; Trastuzumab Emtansine · For: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Sites: Shanghai, China; Tianjin, China
- A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Pivotal-lookingActive, not recruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT04622319 · 1,600 participants (planned) · Start Dec 4, 2020 · Primary completion Jul 2, 2025
Drug: DS-8201a; T-DM1 · For: HER2-Positive Primary Breast Cancer; Residual Invasive Breast Cancer
Sites: Anaheim, California; Baldwin Park, California; Bellflower, California · 482 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01772472 · 1,486 participants · Start Apr 3, 2013 · Primary completion Jul 25, 2018
Drug: trastuzumab; trastuzumab emtansine · For: Breast Cancer
Sites: Anchorage, Alaska; Long Beach, California; Orange, California · 268 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression807
- fatigue759
- nausea741
- off label use647
- diarrhoea605
- death565
- thrombocytopenia485
- neuropathy peripheral457
- platelet count decreased438
- headache436
- metastases to central nervous system409
- drug ineffective406
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 157 |
| 2014 | 296 |
| 2015 | 671 |
| 2016 | 371 |
| 2017 | 377 |
| 2018 | 456 |
| 2019 | 455 |
| 2020 | 619 |
| 2021 | 889 |
| 2022 | 1,039 |
| 2023 | 1,091 |
| 2024 | 1,085 |
| 2025 | 635 |
| 2026 | 307 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kadcyla (Ado-Trastuzumab Emtansine)
2024 spending
$4.1M
Beneficiaries
52
391 claims
Per beneficiary
$77,946
$4,332.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,431,210 |
| 2021 | $4,777,613 |
| 2022 | $4,663,633 |
| 2023 | $3,847,823 |
| 2024 | $4,053,198 |
Part B: Kadcyla (Ado-Trastuzumab Emtansine) · HCPCS J9354
2024 spending
$142M
Beneficiaries
2,206
13,973 claims
Per beneficiary
$64,448
2024 ASP limit $39.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $175,822,576 |
| 2021 | $182,463,589 |
| 2022 | $170,555,487 |
| 2023 | $144,605,154 |
| 2024 | $142,171,218 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.